frank O.

Since its beginning in 1902, Cedars-Sinai has evolved to meet the healthcare needs of one of the most diverse regions in the nation, continually setting new standards for quality and innovation in patient care, research, teaching and community service. Today, Cedars-Sinai is widely known for its national leadership in transforming healthcare for the benefit of patients. Cedars-Sinai receives consistent recognition for our excellence. Our awards include; being named one of America’s Best Hospitals by U.S. News & World Report, receiving the National Research Corporation’s Consumer Choice Award 19 years in a row for providing the highest-quality medical care in Los Angeles, achieving the longest-running Magnet designation for nursing excellence in California, and being recognized as The Advisory Board Company’s 2017 Workplace of the Year, an award Cedars-Sinai has won three years in a row. This annual award recognizes hospitals and health systems nationwide that have outstanding levels of employee engagement. Cedars-Sinai is a leader in the clinical care and research of heart disease, cancer and brain disorders, among other areas. Pioneering research achievements include using cardiac stem cells to repair damaged hearts, developing minimally invasive surgical techniques and discovering new types of drugs to target cancer more precisely. Cedars-Sinai also impacts the future of healthcare through education programs that encompass everything from highly competitive medical residency and fellowship programs to a biomedical science and translational medicine PhD program, advanced training for nurses and educational opportunities for allied health professionals. Most notably, Cedars-Sinai demonstrates a longstanding commitment to strengthening the Los Angeles community through wide-ranging programs that improve the health of its most vulnerable residents.

Founded in San Diego, CA, NuFund is one of the largest, most active and most successful early-stage investor groups over the past 20+ years. We represent diverse backgrounds and perspectives, and work together to foster a culture of excellence, respect, innovation, and fun.

LvlUp Ventures is a global venture capital firm investing in and accelerating early-stage & late-stage startups. LvlUp is ranked among the most active venture capital firms globally (#7 worldwide, #4 in the United States, and #1 in Consumer Goods & Technology — PitchBook). Our opportunistic investment thesis backs founders wherever opportunity emerges—where the intersection of our capital, expertise, and strategic partnership ecosystem unlocks a true level up in growth, unbound by sector or stage. Beyond capital, LvlUp operates as an extended team to founders—combining hands-on growth and fundraising support with a powerful ecosystem of corporate partners to give companies an unfair advantage as they scale. We are deeply focused on unlocking synergies across our portfolio through our extended-team ecosystem, deep corporate partnerships, and a technology backbone designed to create opportunities between companies at scale. LvlUp is powered by a global team of more than 2,500 core and extended members, united by a shared mission: helping founders build enduring, category-defining companies.

ACT Genomics is a world-leading genomic test solution provider. Our mission is to make personalized medicine accessible to all. We offer precision medicine services globally. Combining tumor biology, cancer genomics, and bioinformatics experts to provide treatment guidelines for solid tumors, relapse, and drug resistance, as well as cancer monitoring, risk assessment, and immunotherapy evaluation. We are dedicated to turning every cancer patients genetic information into actionable resolutions through cutting-edge next-generation sequencing (NGS) platforms, bioinformatics analysis, and comprehensive service offerings. Our NGS platform, coupled with sophisticated bioinformatics tools and curated proprietary databases, enables us to deliver reliable results for clinical and research purposes, and our data visualization technologies make the scientific results easily understandable for everyone. Our clinical services include cancer prevention, early detection, treatment selection, and disease monitoring. Our genomic assays offer comprehensive cancer genomic profiling and treatment options for patients with cancer and provide insights into biomarker discovery and patient stratification for clinical trials.

NextGen Venture Partners works with over 1,800 Venture Partners to invest $1 million in seed stage companies and $2 million to $10 million in companies with more than $10 million in revenue. Our Venture Partners are top founders and innovation executives across the country whose expertise and connections help NextGen accelerate the growth of our portfolio companies.

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.